Article
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials.
Pharmacogenetics - 1 Oct 2002
Mascheretti Silvia, Hampe Jochen, Croucher Peter J P, Nikolaus Susanna, Andus Tilo, Schubert Silvia, Olson Allan, Bao Weihang, Fölsch Ulrich Robert, Schreiber Stefan
Abstract excerpt
Infliximab induces remission in 30-40% of patients with active Crohn's disease. Treatment response is a stable trait over repeated doses yet the clinical predictors of response are still unknown. Recently, three variants in the CARD15 gene have been identified as major genetic risk factors for Crohn's disease. Single nucleotide polymorphisms (SNPs) 8, 12 and 13, have been shown to be independently associated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.